GRAIL, a healthcare company focused on detecting cancer early, when it’s most treatable, announced a strategic partnership with athenahealth, a leading provider of network-enabled software and services for medical practices and health systems across the U.S. The collaboration integrates ordering of GRAIL’s Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core, enhancing care coordination and streamlining lab ordering within athenaOne, athenahealth’s flagship cloud-based electronic health record (EHR) platform.
This new integration empowers more than 160,000 clinicians on the athenahealth network to opt-in and seamlessly order the Galleri test directly from their EHR workflow—eliminating manual steps and improving operational efficiency. Once ordered, patients can take the Galleri test kit to a scheduled blood draw appointment. The test results are automatically populated into the patient’s chart, significantly reducing administrative overhead for provider teams.
Also Read: Illumina and Ovation.io Launch Groundbreaking GLP-1 Multiomic Dataset to Accelerate Therapeutic Development
“Cancer remains a public health crisis. There is a clear need to transform the way we screen for cancer while still asymptomatic, when it can be more easily treated,” said Josh Ofman, MD, MSHS, president at GRAIL. “Integrating with athenaCoordinator Core will help simplify the Galleri test ordering process as part of routine exams and help increase patient access to multi-cancer early detection to screen for some of the deadliest cancers before they become symptomatic.”
The Galleri test is designed to detect a signal shared across more than 50 types of cancer—many of which are not typically screened for today-through a simple blood draw. By incorporating this functionality into athenahealth’s network, the partnership aims to expand access to early detection tools and equip clinicians with seamless, technology-enabled options to identify cancer earlier in patients who may not show symptoms.